Lionco(SH:603669) Zheng Quan Ri Bao·2025-12-10 07:59Core Viewpoint - Lingkang Pharmaceutical Group Co., Ltd. has decided not to exercise the downward adjustment of the conversion price for its convertible bonds, despite triggering the conditions for such an adjustment due to stock price performance [2][5][6]. Group 1: Convertible Bond Details - The company issued 5.25 million convertible bonds on December 1, 2020, with a total amount of 525 million yuan and a maturity of 6 years [3]. - The initial conversion price was set at 8.81 yuan per share, which has been adjusted multiple times, with the latest price being 6.50 yuan per share [3][4]. - The conversion period for the bonds is from June 7, 2021, to November 30, 2026 [6]. Group 2: Price Adjustment Conditions - As of December 9, 2025, the stock price has been below 85% of the current conversion price for at least 15 trading days within a 30-day period, triggering the price adjustment clause [2][5]. - The board of directors has decided not to propose a downward adjustment for the conversion price, considering various factors including the company's fundamentals and market conditions [5][6]. - If the conditions for downward adjustment are triggered again within the next month, the company will still not propose an adjustment, and the board will reassess the situation starting January 12, 2026 [2][6].